Alphatec Holdings, Inc. (ATEC) SEC Filings & Earnings Calls

GAAP net loss persists despite non-GAAP profitability, driven by high interest expense, amortization, and stock-based compensation.

“GAAP net loss of $26M vs non-GAAP net income of $11M; significant non-cash and financing costs.”

Dependence on surgeon adoption and procedural volume growth; competitive spine market with large incumbents.

“Growth driven by case volume (+20%) and surgeon adoption (+24%); market is competitive with established players.”

Debt refinancing risk

“We have $63.3 million outstanding under the 2026 Notes which mature in August 2026.”

Litigation exposure

“We are and may become involved in various legal proceedings arising from our business activities.” · word for word

GAAP net loss of $34M indicates ongoing profitability challenges on a GAAP basis.

“GAAP net income / (loss) ($34) million” · word for word

High leverage and debt service costs

“Interest expense, net, increased $3.9 million, or 49%, during the three months ended March 31, 2026, compared to the same period in 2025. The increase in interest expense, net, was primarily due the amortization of debt discount associated with the 2030 Notes.” · word for word

Significant cash burn for capex

“We used cash of $19.9 million in investing activities for the three months ended March 31, 2026, which is primarily related to the purchase of surgical instruments to support the growth of our business and commercial launch of new products and a $5.0 million note receivable.” · word for word

Continued net losses

“Net Loss ($ thousands) 2025: (143,358)”

High executive compensation dilution risk

“Proposed 2026 Equity Incentive Plan adds 12M new shares; 2026 ESPP adds 2M shares.”

Loss of board experience and reduced board size may affect governance oversight

“Board size reduced from 8 to 7 following director retirement”

Litigation expense increase

“Litigation-related expenses increased by $14.0 million, or 143%, during the year ended December 31, 2025, compared to the year ended December 31, 2024.” · word for word

High leverage and debt service costs

“Interest expense, net, increased $21.0 million, or 85%, during the year ended December 31, 2025, compared to the year ended December 31, 2024.” · word for word

Dependence on surgeon adoption and new product launches for growth; competitive spine market.

“Growth driven by net new surgeon users and Valence system launch; competitive dynamics not detailed.”

Integration risk from OsteoAdapt distribution rights

“Acquisition of exclusive distribution rights; integration may pose challenges.”

Loss of board member may require replacement, but no immediate impact.

“Passing of board member.”

GAAP net loss of $29M indicates significant non-cash charges (amortization, litigation) that may persist.

“GAAP net income / (loss) ($29) million; Non-GAAP adjustments include amortization of acquired intangible assets and litigation-related expenses.” · word for word

Dependence on surgeon adoption and procedural volume growth; any slowdown could impact revenue.

“Net new surgeon users growth is a key leading indicator; surgical revenue growth of 31% is driven by PTP and LTP products.”

Litigation Expense Risk

“Litigation-related expenses increased $4.4 million, or 212%, and $11.7 million, or 136%, for the three and nine months ended September 30, 2025, respectively, compared to the same period in 2024.” · word for word

Debt Service Risk

“Interest expense, net, increased $6.3 million, or 96%, and $15.3 million, or 86%, during the three and nine months ended September 30, 2025, respectively, compared to the same period in 2024.” · word for word